|
|
 |
Developing and manufacturing revolutionary, low-cost, high-performance flow cytometers for researchers. |
Acquired |
2011 |
 |
|
|
 |
Developing new class of therapeutic compounds. |
Acquired |
2007 |
 |
|
|
 |
Discovery, development and commercialization of prescription pain management products |
IPO |
2000 |
|
|
|
 |
Internet-based medical monitoring systems for patients with chronic diseases |
Acquired |
2007 |
 |
|
|
Anesta Corporation |
Powerful drug system to control the severe pain of end stage cancer |
Acquired |
2000 |
 |
|
|
 |
Technology and products to treat cancers, infectious diseases, and autoimmune disorders |
IPO |
2000 |
|
|
|
 |
Pioneer and global market leader in brain monitoring and measurement products |
Acquired |
2010 |
 |
|
|
AudioLogic, Inc. |
High performance digital signal processing systems |
Acquired |
1999 |
 |
|
|
 |
Discovering, developing and commercializing cancer therapeutics. |
IPO |
2010 |
|
|
|
 |
Novel diagnostics to improve patient outcomes and contain healthcare costs. |
IPO |
2011 |
|
|
|
 |
Sequenced human genome; now focused on therapeutics for cancer and other diseases |
IPO |
2000 |
|
|
|
 |
Developing small molecule therapeutics for multiple oncology and immunology-based indications |
Acquired |
2010 |
 |
|
|
ChemGenics Pharmaceuticals |
Genetically directed drug discovery focused on fungal bacterial diseases |
Acquired |
1997 |
 |
|
|
 |
Pioneer in the design, marketing and licensing of intelligent solid-state lighting systems |
Acquired |
2007 |
 |
|
|
 |
Design, development, manufacturing, and marketing of medical devices focused on women's health |
IPO |
1996 |
|
|
|
 |
Developing novel protein measurement systems based on Protien Epitope Tag technology |
Acquired |
2009 |
 |
|
|
 |
Proprietary technologies for the early detection, monitoring and staging of common cancers |
IPO |
2001 |
|
|
|
 |
Large repository of human DNA, serum and tissue samples linked to detailed clinical information |
Acquired |
2006 |
 |
|
|
 |
Innovative genetic analysis technologies for the development and marketing of molecular diagnostics tests. |
IPO |
2007 |
|
|
|
 |
Platform technology enabling novel therapies for treatment of sleep disorders |
Acquired |
2007 |
 |
